Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant)

Vincenzo Sammartanoa Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

Adele Santonia Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

Bruno Fredianib Rheumathology Unit, COVID Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

Anna Sicuranzaa Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

Cencini Emanuelea Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

Federico Franchic Anesthesia and Intensive Care Unit, COVID Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

Enrico Capochianid Hematology Unit, Azienda USL Toscana NordOvest, Center for Translational Medicine, Livorno, Italy

Monica Bocchiaa Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, ItalyCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Author contributions

MB has the original idea to report the case and treatment purposes and she coordinated the working group. BF, FF, EC and EC managed the patient; VS and AS managed the patient and wrote the paper; AS wrote the paper. All authors revised and approved the final version of the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant)

Information for

Open access

Opportunities

Help and information

Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant)

Author contributions

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature